Aerie Pharmaceuticals, Inc.
シンボルマーク: AERI
NASDAQ
15.25
USD今日の市場価格
-9.4457
PER(株価収益率
0.2147
PEGレシオ
753.62M
MRK キャップ
- 0.00%
DIV利回り
Aerie Pharmaceuticals, Inc. (AERI) 財務諸表
貸借対照表
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 691.88 | 139.8 | 240.4 | 309.2 | |||||||||||
balance-sheet.row.short-term-investments | 504.72 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.net-receivables | 364.41 | 158.8 | 56 | 38.4 | |||||||||||
balance-sheet.row.inventory | 174.37 | 40.4 | 27.1 | 21.1 | |||||||||||
balance-sheet.row.other-current-assets | 56.18 | 16.6 | 8.3 | 7.7 | |||||||||||
balance-sheet.row.total-current-assets | 1286.84 | 355.6 | 331.8 | 376.3 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 290.73 | 74.1 | 68.3 | 58.1 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 3.98 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 6.32 | 1.6 | 1.9 | 18.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 301.03 | 75.7 | 70.3 | 76.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.account-payables | 34.5 | 8.3 | 8.8 | 12.8 | |||||||||||
balance-sheet.row.short-term-debt | 18.45 | 4.4 | 4.9 | 5.5 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 1253.65 | 256.3 | 210.4 | 188.7 | |||||||||||
Deferred Revenue Non Current | 275.63 | 64.3 | 50.9 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 164.69 | 48 | 39.9 | 65.4 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 1542.75 | 323.7 | 273.6 | 202 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 101.17 | 26.1 | 15.1 | 17.6 | |||||||||||
balance-sheet.row.total-liab | 2036.03 | 448.7 | 378.1 | 285.7 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.19 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -4645 | -1153.9 | -1079.1 | -896 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.15 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 4198.8 | 1136.7 | 1103.1 | 1063 | |||||||||||
balance-sheet.row.total-stockholders-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1587.87 | - | - | - | |||||||||||
Total Investments | 508.71 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.total-debt | 1272.1 | 260.6 | 215.3 | 194.2 | |||||||||||
balance-sheet.row.net-debt | 1084.93 | 223.5 | 63.7 | 50.2 |
キャッシュフロー計算書
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 18.4 | 29.5 | 40.1 | 45.1 | |||||||||||
cash-flows.row.change-in-working-capital | 5.69 | -92.6 | 44.9 | -24 | |||||||||||
cash-flows.row.account-receivables | -9.31 | -12.8 | -17.7 | -35.6 | |||||||||||
cash-flows.row.inventory | -15.16 | -12.1 | -5.2 | -10.3 | |||||||||||
cash-flows.row.account-payables | -7.51 | 21.6 | 16.9 | -270.8 | |||||||||||
cash-flows.row.other-working-capital | 37.68 | -89.2 | 50.9 | 292.7 | |||||||||||
cash-flows.row.other-non-cash-items | -0.53 | 1.2 | -0.7 | 9.9 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 7.17 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -165.66 | -132.4 | -116.6 | -165.5 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 151.88 | 117.5 | 192.9 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -7.8 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -18.3 | -18.2 | 73.2 | -183.2 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -8.3 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 2.42 | 3 | -0.9 | 0.7 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.96 | 0 | 8.3 | 274.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 3.38 | 3 | -0.9 | 274.8 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -7.75 | -114.4 | 7.6 | -58.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 187.16 | 37.2 | 151.6 | 143.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 194.92 | 151.6 | 143.9 | 202.8 | |||||||||||
cash-flows.row.operating-cash-flow | 7.17 | -99.2 | -64.7 | -150.4 | |||||||||||
cash-flows.row.capital-expenditure | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.free-cash-flow | 2.64 | -102.4 | -67.8 | -160.4 |
損益計算書の行
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 213.94 | 194.1 | 83.1 | 69.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 23.52 | 26.8 | 25.3 | 4.8 | |||||||||||
income-statement-row.row.gross-profit | 190.42 | 167.3 | 57.8 | 65.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 87.57 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.operating-expenses | 217.13 | 213.6 | 213.5 | 252.5 | |||||||||||
income-statement-row.row.cost-and-expenses | 240.65 | 240.5 | 238.8 | 257.4 | |||||||||||
income-statement-row.row.interest-income | 0.88 | 0.1 | 2 | 3 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
income-statement-row.row.ebitda-caps | -3.07 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -23.24 | -45.3 | -155.7 | -187.5 | |||||||||||
income-statement-row.row.income-before-tax | -35.23 | -74.2 | -177.9 | -199.7 | |||||||||||
income-statement-row.row.income-tax-expense | 1.32 | 0.6 | 5.2 | -0.1 | |||||||||||
income-statement-row.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 |
よくある質問
Aerie Pharmaceuticals, Inc.AERI 総資産とは何ですか?
Aerie Pharmaceuticals, Inc. (AERI) 総資産は 431391000.000.
企業の年間売上高とは?
年間収益は 69440000.000である.
企業の利益率は?
利益率は 0.862 である.
企業のフリーキャッシュフローとは?
フリーキャッシュフローは -2.211.
企業の純利益率は?
純利益率は -0.385 である.
企業の総収入は?
総収入は -0.233 である.
Aerie Pharmaceuticals, Inc. (AERI) 純利益(純利益)とは何ですか?
純利益(純利益)は -74810000.000.
負債総額は?
負債合計は 260643000.000 である.
営業費用はいくらですか?
営業費用は 213642000.000 である.
会社の現金はいくらですか?
企業の現金は 54093000.000 である.